Back to top
more

Epizyme, Inc. (EPZM)

(Delayed Data from NSDQ)

$12.10 USD

12.10
622,659

+0.19 (1.60%)

Updated May 3, 2019 04:00 PM ET

After-Market: $12.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

by Zacks Equity Research

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More

by Zacks Equity Research

Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.

Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen

by Zacks Equity Research

Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.

Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?

by Zacks Equity Research

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates

by Zacks Equity Research

Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.

Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -31.75% and 86.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

by Kanishka Das

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Epizyme (EPZM) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Epizyme (EPZM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report?

by Zacks Equity Research

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Voyager Therapeutics (VYGR) Surges 12.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

by Zacks Equity Research

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

by Zacks Equity Research

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.

Epizyme (EPZM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.

Is a Surprise Coming for Epizyme (EPZM) This Earnings Season?

by Zacks Equity Research

Epizyme (EPZM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 54.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Epizyme (EPZM)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Epizyme (EPZM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Epizyme (EPZM) Stock Dives on Public Offering of Common Stock

by Zacks Equity Research

Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up

by Zacks Equity Research

Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.

Epizyme (EPZM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of -42.22% and -40.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Epizyme (EPZM) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe

by Zacks Equity Research

While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.